Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nintedanib in Recurrent or Persistent Endometrial Carcinoma
NCT01225887Phase 2Completed
- Sponsor
- GOG Foundation
- Start
- Oct 2011
- Primary completion
- Jan 2016
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of nintedanib in endometrial carcinoma, sponsored by GOG Foundation. Started Oct 2011; status: completed.
02
Drugs
nintedanib
03
Conditions
endometrial carcinoma
Beyond the preview
Go deeper on NCT01225887.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01225887.